A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517614-14-00

Acronym

IMVT-1402-2401

Enrollment

Registered

2025-10-28

Start date

2025-11-28

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Brief summary

The proportion of participants remaining Relapse-free by Week 24.

Detailed description

Change from baseline to Week 24 in I-RODS., Change from baseline to Week 24 in Mean Grip Strength in the dominant hand., Change from baseline to Week 24 in MRC-SS., Change from baseline to Week 24 in aINCAT score.

Interventions

DRUGPlacebo is identical to IMP but with no active substance.

DRUGIMVT-1402

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of participants remaining Relapse-free by Week 24.	—

Secondary

Measure	Time frame
Change from baseline to Week 24 in I-RODS., Change from baseline to Week 24 in Mean Grip Strength in the dominant hand., Change from baseline to Week 24 in MRC-SS., Change from baseline to Week 24 in aINCAT score.	—

Countries

Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026